gliclazide has been researched along with Innate Inflammatory Response in 5 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A diet-induced non-alcoholic fatty liver disease (NAFLD) model causing obesity in rodents was used to examine whether sitagliptin and gliclazide therapies have similar protective effects on pathological liver change." | 8.12 | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. ( Gorrell, MD; McLennan, SV; Ren, J; Twigg, SM; Wang, X; Yee, C, 2022) |
| "A diet-induced non-alcoholic fatty liver disease (NAFLD) model causing obesity in rodents was used to examine whether sitagliptin and gliclazide therapies have similar protective effects on pathological liver change." | 4.12 | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. ( Gorrell, MD; McLennan, SV; Ren, J; Twigg, SM; Wang, X; Yee, C, 2022) |
| "Treatment with empagliflozin showed a significant amelioration of behavioral/neurological functions and histopathological changes observed in brain tissues of hyperglycemic rats subjected to cerebral I/R injury." | 1.56 | Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. ( Abdel-Latif, RG; Amin, EF; Rifaai, RA, 2020) |
| "Treatment with gliclazide alone decreased serum glucose, total cholesterol, triglycerides, malondialdehyde, tumor necrosis factor-alpha and nuclear factor kappa-Beta while increased serum C-peptide, superoxide dismutase, reduced glutathione and adiponectin levels." | 1.56 | New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats. ( Abdelkader, NF; Badawi, MA; Eitah, HE; Gamaleldin, AA; Kenawy, SA; Maklad, YA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Ren, J | 1 |
| Wang, X | 1 |
| Yee, C | 1 |
| Gorrell, MD | 1 |
| McLennan, SV | 1 |
| Twigg, SM | 1 |
| Amin, EF | 1 |
| Rifaai, RA | 1 |
| Abdel-Latif, RG | 1 |
| Abdelkader, NF | 1 |
| Eitah, HE | 1 |
| Maklad, YA | 1 |
| Gamaleldin, AA | 1 |
| Badawi, MA | 1 |
| Kenawy, SA | 1 |
| Räkel, A | 1 |
| Renier, G | 1 |
| Roussin, A | 1 |
| Buithieu, J | 1 |
| Mamputu, JC | 1 |
| Serri, O | 1 |
1 trial available for gliclazide and Innate Inflammatory Response
| Article | Year |
|---|---|
Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Gliclazi | 2007 |
4 other studies available for gliclazide and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Diet, High-Fat; Gliclazide; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Male; Mice; | 2022 |
Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Models, Animal; Gliclazide; Glucosides; Hyperglyce | 2020 |
New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus, Experimental; Drug Therapy, Combi | 2020 |